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A B S T R A C T 
 
In many biomedical contexts ranging from chemotherapy to tissue engineering, it is beneficial to 
sequentially present bioactive payloads.  Explicit control over the timing and dose of these 
presentations is highly desirable.  Here, we present a capsule-based delivery system capable of 
rapidly releasing multiple payloads in response to ultrasonic signals. In vitro, these alginate 
capsules exhibited excellent payload retention for up to 1 week when unstimulated and delivered 
their entire payloads when ultrasonically stimulated for 10 to 100 s.  Shorter exposures (10 s) 
were required to trigger delivery from capsules embedded in hydrogels placed in a tissue model 
and did not result in tissue heating or death of encapsulated cells.  Different types of capsules 
were tuned to rupture in response to different ultrasonic stimuli, thus permitting the sequential, 
on-demand delivery of nanoparticle payloads.  As a proof of concept, gold nanoparticles were 
decorated with bone morphogenetic protein-2 to demonstrate the potential bioactivity of 
nanoparticle payloads.  These nanoparticles were not cytotoxic and induced an osteogenic 
response in mouse mesenchymal stem cells.  This system may enable researchers and physicians 
to remotely regulate the timing, dose, and sequence of drug delivery on-demand, with a wide 
range of clinical applications ranging from tissue engineering to cancer treatment.  
 
 
 
1. Introduction 
 
Biological and physiological systems conduct themselves with a high degree of temporal 
complexity. This often demands drug delivery strategies that are capable of directing biological 
processes with temporal nuance [1,2]. Furthermore, in certain instances, control over not only the 
timing but the sequence of biomolecular delivery is highly desired in order to mimic the manner 
by which nature regulates biological processes [3-5].  However, contemporary polymer-based 
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drug delivery materials that rely on diffusion or degradation typically provide either constant 
rates of release over protracted periods of time or predefined sequences of drugs [6,7]. 
Implantable materials that deliver payloads in response to external cues (i.e., pH [8], temperature 
[9], magnetic fields [10-12], electric fields [13,14], and optical signals [15]) provide a means by 
which the timing of different drug deliveries may be externally regulated [1]. External regulation 
of these drug deliveries provides the on-demand flexibility thought to be broadly required in a 
wide range of investigative and clinical scenarios [16].   
Ultrasound is used in a wide range of biomedical contexts, can be administered to 
patients with a high degree of spatiotemporal precision [17,18], and is being explored as a means 
to trigger the release of therapeutics from implantable polymeric systems.  In these hydrogel 
systems, ultrasonic disruption of the polymer and/or the polymer cross-links enables the release 
of incorporated therapeutic payloads [17,19-21].  These ultrasonically responsive systems 
therefore have tremendous potential in a wide range of applications that require localized and 
temporal control over drug delivery.  However, there are several issues with ultrasonically 
responsive systems that currently limit their use in certain applications.  First, triggered 
deliveries from these systems rely on disruptive forces that must be minimized.  For instance, in 
tissue engineering applications it is highly desirable to trigger therapeutic deliveries at lower 
energies in order to minimize the risk of damaging nearby and nascent tissues, preserve the 
structural integrity of implanted scaffolding materials, and preserve the conformation and 
bioactivity of delivered therapeutics.  Second, many ultrasonically responsive systems lack 
adequate payload retention when unstimulated.  Thus, demonstrations of delayed release after 
days to weeks are currently lacking even though some applications may require delayed 
deliveries over these timescales.  For example, in bone regeneration applications, 1-week 
delayed delivery of bone morphogenetic protein-2 (BMP-2) (subsequent to initial inflammatory 
and angiogenic stages) may be beneficial [5,23-25].  Finally, the ability to sequentially trigger 
multiple payloads from ultrasonically responsive system has not yet been demonstrated, despite 
its need in many biomedical applications.  For example, sequential delivery of pro-angiogenic 
and pro-maturation factors is thought to enhance the development of large and mature 
vasculature [3,4].  In cancer treatments, it is thought that the efficacy of chemotherapeutics can 
be enhanced by first delivering agents that make cancer cells more vulnerable to the 
chemotherapeutic [26].  For instance, it has been suggested that sequential 5-fluorouracil (5FU) 
and irinoteacan deliveries may enhance the toxicity of 5FU [27].   
Taking these limitations and demands as motivation, we endeavored to develop 
polymeric capsules that possess several attributes that are desirable in a broad range of 
investigative and clinical scenarios.  More specifically, these capsules were designed to retain 
nanoparticle payloads for up to a week and release their payloads at rates dictated by the 
intensity and duration of applied ultrasonic signals.  Importantly, the ultrasonic signals required 
to trigger these releases were intended to not cause appreciable heating or damage to cells and 
tissues.  These capsules were also designed to provide sequentially triggered payload deliveries.  
That is, capsules could be engineered with different susceptibilities to ultrasonic rupture (i.e., 
weaker versus stronger capsules made by using different types and amounts of cross-linker). 
Thus, systems integrated with both strong and weak capsules could be triggered to first release 
payloads contained in weaker capsules without triggering release from stronger capsules.  More 
intense ultrasonic exposures can be used to subsequently trigger release of payloads contained in 
stronger capsules.  The capsule-based materials described in this work were made from ionically 
cross-linked alginate, whose properties are conducive to a wide variety of biomedical 
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applications as it is non-toxic, minimally immunogenic, and can be modified in a manner that 
permits tunable biodegradability [28]. We therefore believe that these capsules will be highly 
useful in a variety of applications that require flexible, on-demand control over the timing, dose, 
and sequence of multiple therapeutic payload deliveries.    
  
 
2. Materials and methods 
 
2.1. Synthesis and decoration of gold nanoparticles  
 
Gold nanoparticles (AuNPs) were synthesized via citrate reduction as described in 
previous work [29].  0.4 L of 98.5 µg/mL gold (III) chloride trihydrate (Sigma Aldrich, St. 
Louis, MO) was magnetically stirred and heated to a rolling boil. 10 mL of 7.5 mg/mL sodium 
citrate (Sigma Aldrich) solution was rapidly added, leading to the formation of AuNPs of 
roughly 25 nm diameter. The solution was allowed to cool at room temperature. Deionized water 
was added to a final volume of 0.4 L.  To decorate AuNPs with bone morphogenetic protein-2 
(BMP-2), we adopted a similar strategy as described in Kim et al. [28] for decorating AuNPs 
with a different growth factor—vascular endothelial growth factor (VEGF).  1 µg of recombinant 
human BMP-2 (R&D Systems, Minneapolis, MN) was diluted in 120 μL of deionized water and 
added in 40 μL increments to 120 μL stock AuNP solution with 20-minute room temperature 
incubations on a rocker between additions. The solution was then left overnight on the rocker at 
room temperature, followed by four centrifugation-washes at 13000 RCF for 20 min to remove 
remaining unbound BMP-2.  To produce PEGylated AuNPs in control experiments, AuNPs were 
incubated with 10 mL 0.1 mM 2 kDa thiol-mPEG (JenKem Technology USA, Plano, TX) at 
room temperature overnight, stirring, followed by four centrifugation-washes at 13,000 RCF for 
20 min each to remove unreacted PEG. 
 
2.2. Synthesis of alginate capsules  
 
 In order to make ultrasonically burstable capsules, cross-linker solutions were prepared 
from particles (AuNPs as described above or in some cases < 5 μm iron (II, III) oxide 
microparticles (Sigma Aldrich)), divalent cation (either calcium chloride or barium chloride 
(Sigma Aldrich)), and 100% w/v sucrose (Sigma Aldrich), stored at 4°C.  A glass dish was filled 
to a depth of 2 cm with 0.25 wt % LF 20/40 alginate solution (FMC BioPolymer, Philadelphia, 
PA). An automatic syringe pump holding a 5-mL syringe fitted with an 18-gauge needle was 
fixed above the dish such that the distance between the needle and the surface of the alginate 
bath was 2 cm. The syringe pump allowed 250 μl of cross-linker solution to drip at a flow rate of 
1 mL/min into the alginate bath, where the divalent cation in the cross-linker solution quickly 
formed a capsule around the payload. After gelation times of 3 to 10 minutes, completed 
capsules were briefly rinsed in deionized water and stored in phosphate-buffered saline (PBS) 
(Sigma).  Images of capsules filled with iron oxide micro-particles were taken on a stereoscopic 
dissection microscope at 4× magnification, and ImageJ was used to quantify capsule diameters.   
To compare the force at failure of different capsules, individual capsules were compressed at a 
uniform strain rate of 2 mm/min on an Instron model 3345 (Instron, Norwood, MA) until 
rupture.   
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2.3. Incorporation of capsules in bulk hydrogel structures 
 
 In order to incorporate ultrasonically responsive capsules in bulk hydrogel structures, 
calcium-cross-linked alginate gels were cast around the capsules.  4 mL of 2.5 wt % alginate 
dissolved in 4-morpholineethanesulfonic acid (MES) buffer (Sigma Aldrich) was mixed with 
900 µL of MES buffer and 100 µL CaSO4 slurry (210 mg/mL of CaSO4 dihydrate (Sigma 
Aldrich) in deionized water).  This mixing was accomplished quickly by linking two 5-mL 
syringes together with a LuerLock connector (W. W. Granger, Inc., Lake Forest, IL) and ejecting 
the mixture into custom cylindrical, 9-mm-diameter Teflon molds prefilled with capsules.  These 
capsule-incorporated gels were allowed to set for 30 minutes and then stored in PBS.  The 
resulting gels contained 2 wt % alginate with a calcium cross-linking concentration of 5 mM. 
 
2.4. Ultrasonic exposure experiments 
 
 Capsules were exposed to ultrasonic energy in a number of manners.  In all studies, a 
Vibra-Cell VCX 130 sonicator (Sonics & Materials, Inc., Newtown, CT) was used with a 13-mm 
probe (Sonics, Newton, CT). The ultrasonic signals used here were administered to samples at 
various input amplitudes (20%, 40%, and 80%) as indicated in the readout on the Vibra-Cell 
VCX 130’s display.  Measurements indicating the ultrasonic intensities associated with these 
amplitude percentages are included in Appendix A: Supplementary Data.  For experiments 
where capsules were exposed to ultrasound while suspended in solution, a total of 250 μl of 
AuNP-containing capsules (~20 capsules, each containing AuNP concentrations of 211.2 μg/mL) 
were placed in a 50 mL conical tube with 5 mL of PBS. The sonicator was positioned in the 
center of the tube 2 cm from the bottom and delivered a range of ultrasonic doses.  Doses were 
defined by two metrics: ultrasound amplitude (20% to 80% as read from the sonicator’s display) 
and duration (1 to 500 s).  All ultrasonic exposures used 20 kHz signals.  Immediately after 
sonication, a sample of solution was collected and its AuNP concentration was quantified by 
optical absorption (518 nm) with a plate reader (BioTek Instruments, Inc., Winooski, VT) 
against a standard of known AuNP concentrations.   
 For experiments using chicken carcasses, capsules containing iron oxide micro-particles 
or bulk gels containing two capsules each were placed under the skin of chicken wings, medial to 
the ulna, that were warmed in an incubator to 37C. The sonicator probe was coated with 
Aquasonic 100 ultrasound-conducting gel (Parker Laboratories, Inc., Fairfield, NJ) and lowered 
such that the gel bridged the gap between the sonicator probe and the tissue surface. Ultrasound 
was applied at 20% or 80% amplitude for ten seconds. The temperature of the treated tissue (the 
surface of the skin facing the gel) was measured by a thermocouple probe immediately before 
and after sonication.  Iron oxide microparticles were incorporated into capsules in these studies 
so that ultrasonic rupture was visually apparent.   
 
2.5. Nanoparticle toxicity and bioactivity studies 
 
Clonally derived mouse bone marrow stromal mesenchymal stem cells (D1 mMSCs, 
ATTC, Manassas, VA) – which have previously been used in osteogenesis studies [30] – were 
used in all viability studies and bioactivity studies.  mMSCs were seeded at 10,000 cells/cm2 and 
cultured in standard Dulbecco’s Modified Eagles Medium (DMEM, Invitrogen, Carlsbad, CA) 
with 10% fetal bovine serum and 1% penicillin/streptomycin (Invitrogen), at 37°C and 5% CO2.  
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During experiments, media was refreshed every three days.  mMSC viability was quantified via 
live-dead staining (Invitrogen) after 7 days of exposure to AuNPs and controls. Representative 
images from an epifluorescent microscope were processed using ImageJ software in order to 
quantify viability percentages.  In experiments where the cell count and viability of mMSCs 
were quantified after having been encapsulated in bulk alginate hydrogels, alginate gels were 
dissolved by submerging them in a solution of 50 mM ethylene-diaminetetraacetic acid (EDTA, 
Sigma Aldrich) in PBS for 10 minutes at 37°C.  mMSCs were then collected and analyzed for 
cell count (cell counter, Beckman Coulter, Inc., Pasadena, CA) and viability (live-dead staining, 
Invitrogen).   
mMSC differentiation was measured in order to demonstrate the bioactivity of BMP-2-
decorated AuNPs.  In these differentiation studies osteogenic-supplemented medium (osteo-
DMEM) was used that consisted of DMEM supplemented with 50 μg mL-1 L-ascorbic acid and 
10 mM β-glycerophosphate (Sigma Aldrich).   Differentiation of mMSCs was measured by the 
activity of alkaline phosphatase (ALP) in cells seeded in a 48-well plate at 10,000 cells/well and 
cultured for 1 week. 10 μl of 4-methylumbelliferyl phosphate disodium salt (MUP, Sigma 
Aldrich) was added to each well and incubated for 25 minutes at 37°C.  ALP was quantified with 
a plate reader (Biotek, excitation/emission = 360 nm/440 nm) using bovine ALP (Sigma Aldrich) 
to generate a standard curve.  The ALP activity per well was normalized to mMSC cell count in 
each well.  
 
2.6. Data representation and statistical analyses 
 
 All quantitative data were represented as means ± standard deviation.  The majority of 
statistical comparisons were limited to a single comparison.   For these single comparisons, a 
student t-test was applied to calculate significance with p-values of less than 0.05 being the 
benchmark for significance.  For instances where multiple comparisons were made across groups 
(i.e., Fig. 4 D), one-way Analysis of Variance (ANOVA) with a Tukey’s post hoc test was 
utilized.   Throughout this work, unless otherwise stated, the following convention was used to 
indicate the level of significance: *, **, and *** indicate p < 0.05, 0.01, and 0.001, respectively.  
“n.s.” indicates that no statistical significance was found.  
 
 
3. Results and discussion 
 
3.1. Ultrasonically responsive capsule fabrication and characterization 
 
 Alginate capsules were designed to rapidly rupture in response to ultrasonic signals.  A 
solution containing divalent cations (i.e., calcium or barium chloride), sucrose (to make the 
droplets less buoyant when placed in the alginate bath), and payloads (i.e., gold nanoparticles or 
iron oxide microparticles) was added dropwise to an alginate bath (Fig. 1 A(i)).  Once in the 
bath, these droplets released their divalent cations to the surrounding polymer solution (Fig. 1 
A(ii)) eventually forming a cross-linked alginate network as a capsule wall (Fig. 1A (iii)).  This 
process resulted in alginate capsules that encapsulated deliverable payloads (Fig. 1 A(iv), here 
containing dark iron oxide microparticles for higher visual contrast).  These capsules were 
roughly 4 mm in diameter with 0.5 mm walls (Fig. 1 B).  These capsules were capable of 
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releasing iron oxide microparticles in a matter of seconds when ultrasonically stimulated (Fig. 1 
C).   
 
 
 
Fig. 1. Alginate capsules can be fabricated to rupture in response to ultrasound. (A) Schematic of the capsule 
fabrication process: (i) droplets containing divalent cations, sucrose, and nanoparticle payloads are added drop-wise 
to an alginate bath, (ii) once submerged, these droplets release divalent cations which interact with the alginate, (iii) 
eventually forming an ionically cross-linked capsule wall. (iv) A representative microscopic image of a capsule 
loaded with iron oxide particles formed using 50 mM CaCl2. (B) Histograms of capsule diameter and wall thickness 
(i,ii) distributions and (iii) comparisons of mean values ± standard deviations (N = 8).  (C) Images of 10 mL PBS 
solutions containing iron-oxide-loaded capsules when subjected to the indicated ultrasonic signals for 5 seconds. 
These experiments were conducted in glass scintillation vials with the 13-mm ultrasound probe placed 2 cm above 
the capsules.  
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3.2. Triggered delivery of gold nanoparticles 
 
 In order to characterize the payload retention and ultrasonically stimulated release 
capabilities of these capsules, they were loaded with gold nanoparticles (Fig. 2 A, inset) and 
stimulated with ultrasound after being submerged in PBS for 7 days. Capsules released low 
percentages of their payloads over the course of 7 days when not ultrasonically stimulated (Fig. 2 
A and B).  When ultrasonically stimulated on day 7 at 20% amplitude for 100s, gold nanoparticle 
release rapidly transitioned from 1.3% to 100% release (Fig. 2 A).  This corresponded to a 
~400,000-fold increase in release rate from 3.4 × 10-5 to 17.5 μg/min (Fig. 2 B).  These data 
demonstrate the ability to retain molecular payloads for days and deliver them rapidly in an on-
demand manner.  We attribute these capsules’ excellent nanoparticle retention capabilities to the 
inability of nanoparticles to traverse the capsule wall.  The gold nanoparticles used here were 
greater than 10 nm while the pore size of the alginate hydrogel comprising the capsule walls was 
on the scale of single-digit nanometers [28].  While several ultrasonically responsive drug 
delivery systems have recently reported excellent retention capabilities, our system’s stimulated 
delivery over unstimulated delivery (~400,000-fold vs. 5000- [22] and 14-fold [31] 
enhancements) and prolonged retention (7 days (or 168 hours) vs. 30 s [32] and 30 min [33]) 
represent considerable improvements.  The timescales of delayed delivery afforded by these 
capsules (several days to a week) may provide improvements in tissue engineering strategies 
over typical delivery systems that provide initial burst release profiles [34] or sustained release 
[6,7].   
Capsules were also exposed to ultrasonic signals of various intensities and durations in 
order to quantify the relationship between ultrasonic stimulus and the amount of payload 
released.  For example, when exposed to ultrasound at 20% amplitude, ultrasonic exposures of 
roughly 10 to 100 seconds corresponded to the transition from 0% to 100% nanoparticle release 
(Fig. 2 C, black curve).  At higher ultrasonic percent amplitudes, this transition required shorter 
ultrasonic exposures (Fig. 2 C, blue and red curves).  This demonstrates that not only the timing 
but the amount of payload delivered can be explicitly and remotely regulated using ultrasonic 
stimuli.  While this regulatory capability has been demonstrated in other ultrasonically 
responsive hydrogel [35] and alginate capsule systems [36], the work presented here is notable in 
the use of relatively ephemeral ultrasonic exposures.  The capsules presented here exhibit 100% 
payload release in only 10 to 100 seconds (depending on the ultrasonic amplitude) using 
ultrasonic signals applied in a wide range of other delivery modalities [19-22,31-40]. 
In practical scenarios requiring prolonged retention followed by triggered release, it was 
a concern that these capsules’ retention and regulated release characteristics would change after 
being submerged in physiological media for several days.  Specifically, the calcium cross-links 
in the alginate gel could be replaced by other ions in physiological media (e.g., Na+) over time.  
However, after being submerged in calcium-free PBS for a week, the same ultrasonic durations 
engendered statistically indistinguishable percentages of nanoparticle releases (Fig. 2 D, 
comparing solid and dashed curves).   
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Fig. 2. Capsules retain their nanoparticle payloads for prolonged periods and can be ultrasonically triggered to 
release their payloads.  (A) Percent release over time from gold-nanoparticle-loaded capsules (inset) that were 
exposed to ultrasound on day 7 for 100 s at 20% ultrasound. (B) For the same experiment as presented in part A, the 
rate of nanoparticle release over time. In parts A and B, the red shaded region at day 7 indicates the time when 
capsules were exposed to ultrasound.  (C) The percent release as a function of the duration of ultrasonic exposure for 
capsules exposed to 20% (black), 40% (blue) and 80% (red) amplitudes. Note that the x-axis is log-scale.  (D) 
Percent release as a function of the ultrasound’s duration when exposed to 20% ultrasound for capsules immediately 
after fabrication (solid curve) compared to capsules that sat in PBS for a week (dashed curve). For parts A-D, N = 4. 
In each experiment (A-D), capsules were placed in 50 mL tubes containing 5 mL of PBS with the sonicator’s probe 
being centered azimuthally and placed 2 cm above the bottom of the tube.  
 
 
3.3. Sequential delivery of payloads 
 
 In order to produce capsules that could be ultrasonically ruptured, one after the other, 
capsules were designed with varying susceptibilities to ultrasonic rupture.  This was achieved by 
creating capsules with different amounts and types of cross-linkers.  Capsules made from 
droplets containing 50 mM CaCl2 (Fig. 3 A(i) and Fig. 2 A(iv)) and those containing 100 mM 
BaCl2 (Fig. 3A(ii)) exhibited similar inner diameters but statistically different wall thickness and  
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Fig. 3. Capsules can be engineered with varying strength and susceptibility to ultrasonic rupture to enable 
sequentially triggered payload deliveries.  (A) Microscopic images of (i) weak capsules made by using 50 mM 
CaCl2 and (ii) strong capsules made by using 100 mM BaCl2. Yellow arrows draw attention to the capsule wall 
boundaries. (B) Comparison of weak (red) and strong (blue) capsules’ inner diameter (ID), capsule wall thickness, 
and outer diameter (OD). N = 17-24. (C) Applied force as capsules were compressed at 2 mm/min until failure 
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(indicated by ‘x’) for weak (red) and strong (blue) capsules. Inset: mean ± standard deviations of the forces required 
to rupture weak and strong capsules under compression. N = 8. (D) The percent of gold nanoparticles released from 
strong and weak capsules as a function of ultrasonic exposure duration when exposed to (i) 20% and (ii) 80% 
ultrasound amplitudes. (E) Percent gold nanoparticle release over time for when both weak and strong capsules were 
exposed to 200 s of ultrasound on day 7 at 20% amplitude followed by 100 s of ultrasound five minutes later at 80% 
amplitude.  For parts D and E, N = 4. (F) Images of weak (red) and strong (blue) capsules as they were exposed to 
ultrasound at 80% amplitude for long enough to rupture the weak capsules (10 s), followed by a pause (“no 
ultrasound”), and then an additional ultrasound to rupture the strong capsules (for an 100 additional seconds). Weak 
and strong capsules were loaded with red and blue food coloring, respectively.  
  
 
outer diameters, by design (Fig. 3 B, comparing red and blue bars).  The forces required to 
rupture these thicker-walled “strong” capsules were statistically higher than those required to 
rupture the thinner-walled “weak” capsules (Fig. 3 C, comparing blue data to red data).  Aside 
from the difference in capsule wall thickness, we attributed this enhancement in capsule strength 
to the barium cross-linker, which has been shown to create stronger gels [41].  When both weak 
(red) and strong (blue) capsules were exposed to ultrasound at 20% amplitude for 100s, 100% 
nanoparticle release was observed in the weak capsules while nearly 0% release was observed in 
the strong capsules (Fig. 3 D(i)).  A similar trend was observed when exposing both weak and 
strong capsules to ultrasound at 80% amplitude, where only 10 s of exposure preferentially 
triggered nanoparticle release from the weak capsules (Fig. 3 D(ii)).  This ability to trigger 
delivery from weak capsules preferentially over stronger capsules enables sequential payload 
deliveries.  For example, weak capsules retained their payloads for 7 days (Fig. 3 E).  On day 7, a 
20% amplitude ultrasonic signal could be used to trigger delivery from weak capsules with only 
a statistically insignificant amount of release from the strong capsules (Fig. 3 E, blue and red 
curves just after day 7).   After ultrasound was terminated no additional release from the strong 
capsules was observed until an 80% amplitude ultrasonic signal was administered (Fig. 3 E, blue 
curve at day 7.01).  Thus, payloads from the weak capsules were triggered first, followed by 
triggered delivery from the strong capsules at a later time (i.e., sequential delivery). Sequential 
delivery was also demonstrated by first triggering the delivery of red dye from weak capsules 
without triggering delivery from the strong capsules (Fig. 3 F, at time points earlier than 10 s). 
After this initial ultrasound was terminated, strong capsules remained un-ruptured (Fig. 3 F, 
“after” photograph). When a longer ultrasonic signal was subsequently administered, strong 
capsules ruptured, releasing their payload (Fig. 3F, at time points later than 50 s).  Thus, these 
capsules enabled on-demand, sequentially triggered delivery of two different payloads.   
 To the best of our knowledge, this is the first demonstration of a tuned hydrogel system 
that is capable of being remotely triggered to release two payloads, in sequence, in response to 
independent ultrasonic signals.  Elsewhere, others have demonstrated sequential release potential 
by tuning capsule architecture to provide different diffusive release rates [42] and by tuning 
capsule composition to have differential release responses when exposed to other types of 
triggering stimuli (i.e., when exposed to oil [43], piperidine or HCl [44]).  Noble and coworkers 
[31] demonstrated that hydrogels could be coated differently to endow them with different 
ultrasonically triggered release characteristics.  This hydrogel system exhibited excellent 
retention when unstimulated and differential release characteristics at various ultrasonic 
intensities based on hydrogel coatings.  Lattin and Pitt [32] explored several factors influencing 
the potential tunability of ultrasonically responsive perfluorocarbon-loaded liposomes, including 
liposome size, the type of perfluorocarbon used in the liposomes, the ultrasonic intensity, and the 
ultrasonic frequency.  These studies revealed several instances of preferential delivery when 
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ultrasonically triggered due to liposomal tuning.  We have also previously demonstrated that 
payload size can be tuned to enhance independently triggered control over ultrasonic deliveries 
[22].   While none these previous works explicitly demonstrated sequential delivery vs. time per 
se [22,31,32,43-44], taken along with the current study, these studies demonstrate that there are 
many design strategies one could adopt to generate flexible delivery profiles from these types of 
biomaterial systems. 
 
3.4. Decoration of gold nanoparticles with bioactive protein 
 
 As a proof of concept, it was sought to demonstrate that gold nanoparticles potentially 
encased in these capsules could be decorated with protein and be used to viably induce a 
biological response.  Due to the potential utility of these capsules in delaying deliveries in bone 
regeneration applications, mouse mesenchymal stem cells (mMSCs) were used here to 
characterize nanoparticle bioactivity.  Despite the wealth of research on gold nanoparticles, their 
biological effects, and their application in clinical trials [45,46], gold nanoparticles are not, in 
general, nontoxic, as toxicity depends on their specific functionalization and synthesis [47].  
Therefore, the impact of these particles on mMSC viability was analyzed at the maximum 
possible gold nanoparticle concentration cells might experience upon capsule release (i.e., the 
nanoparticle concentration contained in these capsules: 211.2 μg/ml).  PEGylated gold 
nanoparticles at 211.2 μg/ml resulted in statistically similar mMSC viability levels as did 
controls at 0 μg/ml (Fig. 4 A).  In order to create particles with bioactive effects on mMSCs, 
thiol- or disulfide-gold interactions were used to decorate these gold nanoparticles with BMP-
2—a protein known to differentiate mMSCs down the osteogenic lineage [23].  BMP-2, which 
contains several cysteine residues (Fig. 4 B(i)) and disulfide bonds (Fig. 4 B(ii)), can interact 
with and bind to gold (Fig. 4 B(iii)) in a semi-covalent manner [22,48].  This principle has 
previously been applied to decorate gold nanoparticles with other similarly sized proteins while 
preserving the protein’s bioactivity [29].  The BMP-2 on the gold-nanoparticle conjugates could 
be detected in a dose-dependent manner using enzyme-linked immunosorbent assay (ELISA) 
(Fig. 4 C).  Effective concentrations of BMP-2 were calculated using ELISA and it was 
determined that 2.62 μg/mL of decorated AuNPs was equivalent to 300 ng/mL of unconjugated 
BMP-2. Note that the optical absorbance associated with the gold nanoparticles alone did not 
have detectible influence on the ELISA results unless using relatively high gold nanoparticle 
concentrations (Fig. 4 C, gray bars).    
In order to further verify bioactivity, mMSCs were exposed to these BMP-2-gold-
nanoparticle conjugates and measured for ALP activity, a measure of osteogenic differentiation. 
It was found that exposure of these BMP-2-gold-nanparticle conjugates to mMSCs significantly 
enhanced ALP activity as compared to controls.  2.62 μg/ml of BMP-2-gold-nanoparticle 
conjugates (with an effective concentration of 300 ng/mL of BMP-2 measured by ELISA) 
resulted in similar enhancements in ALP activity as 300 ng/mL of BMP-2 alone (Fig. 4 D, 
comparing “AuNP- BMP” to “300 ng/mL BMP”).  Both these conditions led to statistically 
significant enhancements in ALP activity as compared to controls (Fig. 4 D, comparing “AuNP- 
BMP” and “300 ng/mL BMP” to “DMEM” and “osteo-DMEM”).   Both BMP-2-decorated 
nanoparticles and 300 ng/mL of BMP-2 also led to statistically significant enhancements in ALP 
activity as compared to 10 ng/mL of BMP-2.  By contrast, the ALP-inducing activity of 
PEGylated gold nanoparticles at 2.62 μg/ml was statistically indistinguishable from controls, 
indicating that gold nanoparticles themselves were not primarily responsible for ALP 
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enhancement.  It has been reported elsewhere, however, that PEGylated AuNPs can enhance 
MSC osteogenic differentiation [22,49].     
 
 
 
Fig. 4. The gold nanoparticles loaded into these ultrasonically responsive capsules can be endowed with osteogenic 
bioactivity. (A) (i) Images of live/dead stained mMSCs after exposure to 211.2 μg/mL of gold nanoparticles in 
DMEM for 7 days compared to a control with no nanoparticles. (ii) Quantitation of mMSC viability when exposed 
to gold nanoparticles and controls (N = 4). (B) (i) BMP-2 includes several cysteine residues (ii) which contain 
disulfide bonds which can bind to gold substrates. (C) Detected BMP-2 concentrations when assaying the indicated 
concentrations of undecorated gold nanoparticles (gray) and BMP-2-decorated particles (black).  n.d. indicates that 
no protein was detected using ELISA.  The 211.2 μg/mL condition saturated the assay when using BMP-2-decorated 
nanoparticles. (D) Relative ALP activity (normalized to osteogenically supplemented media) for mMSCs after 7 
days when exposed to the following: moving from left to right, normal culture media (DMEM), osteogenic 
supplemented cell media (osteo-DMEM), osteo-DMEM with 10 and 300 ng/mL of BMP-2, osteo-DMEM with 2.62 
μg/mL of PEG-decorated gold nanoparticles, and osteo-DMEM with 2. 62 μg/mL of BMP-2-decorated gold 
nanoparticles (estimated to be equivalent to 300 ng/mL of BMP-2 when using ELISA) (N = 3-4).  * indicates 
statistically significant differences when compared to both DMEM and osteo-DMEM conditions (p < 0.01) and † 
indicates statistically significant differences when compared to the 10 ng/mL BMP-2 condition (p < 0.05).  
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3.5. Incorporation of capsules in bulk hydrogels 
 
  For use in certain situations, it may be necessary to ultrasonically trigger these capsules 
while incorporated into hydrogel scaffolds that have been placed in tissues.  Both weak and 
strong capsules were loaded with iron oxide microparticles (in order to easily visualize capsule 
rupture), incorporated into 2 wt % alginate gels that were cross-linked with 5 mM calcium 
sulfate, and these constructs were placed under the skin of chicken carcasses (Fig. 5 A, left side 
of figure).  After being ultrasonically stimulated at 20% amplitude for 10 s through the skin, 
weak capsules burst, releasing their iron oxide payloads (Fig. 5 A, image in top row under “After 
20% ultrasound for 10s”).  Note that these ruptured weak capsules were not subsequently 
exposed to an 80% ultrasound signal because they had already ruptured. Strong capsules did not 
release their iron oxide payloads when exposed to this dose of ultrasound (Fig. 5 A, image in 
middle row under “After 20% ultrasound for 10s”).  However, when subsequently stimulated at a 
higher ultrasonic intensity, strong capsules released their payloads (Fig. 5 A, image in middle 
row under “After 80% ultrasound for 10s”).  When weak and strong capsules were integrated 
into the same alginate hydrogel, they were still capable of being sequentially triggered for release 
(Fig. 5 A, bottom row).  That is, when exposed to the more moderate ultrasonic signal, the weak 
capsule in the gel ruptured and the strong capsule did not (Fig. 5 A, bottom row, second image 
from the right). At a later time, when a stronger ultrasonic signal was applied, the strong capsule 
ruptured (Fig. 5 A, bottom row, rightmost image). Note that based on visual inspection the bulk 
hydrogel remained intact after ultrasonic treatment, which would be critical in tissue engineering 
applications requiring a scaffolding material that promotes cell adhesion, proliferation, and 
remodeling [50].  Also note that these ultrasonic signals required here were lower than those 
required to trigger release in experiments where capsules were suspended in PBS (Fig. 3 D).  We 
attributed this to two factors.  One, the ultrasonic probe is closer to the capsules when stimulating 
the implanted gel compared to when stimulated in PBS (a few millimeters as compared to 2 cm).  
Two, when immobilized in a gel and/or a tissue, the ultrasonic energy is allowed to more 
consistently affect the area of the capsule most proximal to the ultrasonic probe, making the 
capsule rupture more efficiently.  When submerged in PBS, these capsules tend to bounce around 
and rotate (Fig. 3 F), making ultrasonic rupture less efficient.   
 In examining another practical consideration, we aimed to determine if the ultrasonic 
energies required to trigger release heated tissues or influenced the viability of cells encapsulated 
within hydrogel scaffolding structures.  When measured, tissue temperatures were similar before 
and after exposure to the ultrasonic does (80% amplitude for 10 s) required to trigger release for 
strong capsules embedded in hydrogels structures inside our tissue model (Fig. 5 B).  
Additionally, when mMSCs were encapsulated in bulk alginate hydrogels and exposed to the 
same ultrasonic signal (80% amplitude for 10 s), their viability and numbers did not decrease in a 
statistically significant manner (Fig. 5 C, viability in black and cell count in grey).  While not 
statistically significant, we attributed the slight reduction in cell count (Fig. 5 C, grey bars) to 
cells lost on the perimeter of the gel, which are more likely to be affected by the ultrasonic 
signal.  Nonetheless, a strong population of live cells remain in the gel after ultrasonic exposure 
(~350,000 live cells per 0.5 mL gel).  Note that the relatively low cell viabilities measured here 
were likely due to these alginate gels not being optimized for mMSC encapsulation (i.e., 2 wt % 
alginate cross-linked with 5 mM calcium sulfate and lacking RGD functionalization for proper 
cell adhesion).   The maintenance of cell viability and tissue temperatures observed here are 
consistent with other reports in that the ultrasonic exposures utilized here are well below those 
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determined to be harmful to cells [51,52].  Finally, in other more sensitive applications, 
improved targeting of these capsules can potentially be achieved through the use of high 
intensity focused ultrasound [53,54]. 
 
 
 
Fig. 5. Capsules can be ruptured when integrated into hydrogels and placed in a chicken carcass tissue model using 
ultrasonic signals that do not result in tissue heating or reductions in cell viability.  (A) Images of iron-oxide-loaded 
capsules integrated into 2 wt % alginate hydrogels that are cross-linked with 5 mM calcium sulfate before, during, 
and after ultrasonic stimulation when implanted under the skin of 37C chicken carcass.  The time over the course of 
each experiment moves from left to right. Note that gels containing only weak capsules (top row) were not 
stimulated at 80% ultrasound since all capsules ruptured using 20% ultrasound. Therefore, an image was not 
acquired for the 80% case.  (B) Tissue temperature before and after exposure to 10 seconds of ultrasound at 80% 
amplitude.  (C) Cell viably (black, left axis) and cell count (grey, right axis) of mMSCs encapsulated in 2 wt % 
alginate hydrogels that are cross-linked with 5 mM calcium sulfate and exposed to 10 seconds of ultrasound at 80% 
amplitude (N = 4).   
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3.6. Applications, limitations, and future directions 
 
 The capsule-based system presented here provides several notable advantages over 
previous work that make it a potentially useful tool for several applications, including bone 
tissue engineering applications. First, because the nanoparticle payloads are too large to diffuse 
out of the hydrogel capsules’ walls, these capsules exhibit excellent payload retention (i.e., 1.3% 
payload release over 7 days, or 0.0078% per hour, see Fig. 2 A). Second, when stimulated, these 
capsules (by design) rupture very rapidly, providing 100% payload release in an efficient manner 
(100% payload release in < 100 s of stimulation, or 1% per second).  In comparison to this lab’s 
previous work [19], these capsules’ 78-fold enhancement in payload retention rate (0.0078 %/h 
compared to ~0.6 %/h) and 730-fold enhancement in stimulated release rate (1 %/s compared to 
0.00137 %/s), enabled the triggered release of payloads efficiently after prolonged periods of 
time (Fig 2 A and B, 7 day retention and rapid 100% release on day 7).  Due to these 
enhancements in both retention and release efficiency, when stimulated, these capsules provided 
a 400,000-fold enhancement in payload release rate over unstimulated release rate, compared to 
the previous system’s 7-fold enhancement.   Finally, because these capsules could be “tuned” to 
rupture at varying degrees of ultrasonic stimulation (Fig. 3 A through D, strong vs. weak 
capsules), payloads could be triggered to release in sequence (Fig. 3 F, first triggered release of 
red payloads from weak capsules followed by a later triggering of blue payloads from strong 
capsules).  This sequenced rupturing of weak then strong capsules was also demonstrated in a 
tissue model (Fig. 5 A). The previous system was limited to releasing single payloads.  In bone 
regeneration, it has been suggested that delaying the delivery of molecules that differentiate 
MSCs into osteoblasts can enhance regenerative outcome [5,23-25]. This system may be useful 
in these strategies since it was shown here that gold nanoparticles could both (i) be 
functionalized with BMP-2 and have a osteo-differentiating effect on MSCs (Fig 4 C and D) and 
(ii) could be retained for at least a week in these capsule systems (Fig. 2 A and B). 
Several other treatment strategies could also benefit from a biomaterial system with the 
above-described capabilities. For example, in cancer treatment, it has been demonstrated that the 
pulsatile delivery profiles that these capsule-based systems can provide result in more efficient 
cancer cell destruction than the mostly constant delivery profiles provided by biomaterials that 
rely on diffusion and/or degradation [19].  This capsule system’s specific ability to sequentially 
deliver one payload followed by a different payload could also provide further advancements in 
cancer treatment. For instance, in emerging anticancer strategies, more resistant cancer cells can 
be rendered less resistant by exposing them to a secondary agent [26].  However, selecting the 
right timing and sequence [27] of these independent deliveries will be critical in optimizing these 
clinical strategies.  The material system described here may be useful in experimentally 
determining these optimized timings and sequences.  In vaccine therapies, many important 
immunizations require several boosters in sequence following initial inoculation [55]. Several 
microsphere-based systems have been developed for single-administration vaccines [56-59].  
The system described here could provide flexibility over the timing of these boosts and enable 
longer sequences of boosts.  
However, before these capsule-based systems can be utilized in these and other 
biomedical contexts, several future studies will be required. In bone regeneration applications, 
the osteo-differentiating capacity of BMP/AuNP constructs must be verified before and after 
ultrasonically stimulated release.  In cancer therapy applications, AuNPs that are functionalized 
with anticancer agents must be developed and the therapeutic impact of these AuNP constructs 
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must be verified before and after sonication. Similarly, for vaccine inoculation and boosting, 
AuNPs must be created that are functionalized with antigen and adjuvants and verified to retain 
bioactivity before and after ultrasonically triggered release. Importantly, in both these and other 
applications, experiments must be conducted in live animal models. While the studies described 
here have demonstrated that these capsules can be ultrasonically ruptured in a tissue model, 
future studies will be required to fully characterize these system’s capabilities in live animals.  
Specifically, though it was demonstrated here that AuNP delivery can be triggered after a week 
in vitro, demonstrating triggered delivery after prolonged implantation in live animals will be a 
critical step in applying these materials in therapeutic strategies.  In these applications, it is of 
note that alginate in pure forms is well-known to cause minimal inflammation when implanted 
[28].  
 
 
4. Conclusions 
 
We have created alginate capsules that can deliver nanoparticle payloads upon 
application of ultrasonic stimuli. On-demand deliveries after storage times of up to one week in 
vitro were demonstrated, even in calcium-free buffer.  The enhancement in release rate with 
stimulation was ~ 400,000-fold, as compared to the unstimulated release rate.  Additionally, the 
amount of release could be regulated by the intensity and duration of the applied ultrasonic 
signal.  We have also demonstrated that release from these capsules can be tuned by controlling 
the amount and type of cross-linker in the capsule walls.  This enabled sequential payload 
delivery by first rupturing weakly cross-linked capsules, followed by more strongly cross-linked 
capsules.  When integrated into bulk alginate hydrogel scaffolds and placed under the skin in a 
chicken carcass tissue model, these capsules retained their ability to be sequentially ruptured 
using ultrasonic stimuli.  Payload deliveries from these capsules were rapid: 100 % release when 
ultrasonically stimulated in under 100 s in vitro.  However, when triggering release from 
capsules that were integrated in alginate scaffolds and placed in a chicken carcass tissue model, 
less than 10 s of ultrasound was required.  This amount of ultrasonic stimulation did not result in 
measurable increases in tissue temperature or death of mMSCs encapsulated in the scaffolds.  
We believe that these demonstrated capabilities will be of great investigative value for 
examining how the timing, sequence, and dose of various biomolecules influence outcomes in 
cancer and tissue engineering research.  We also believe that the on-demand capabilities that 
these capsules provide will have strong clinical applicability in situations where the timing, dose, 
and sequence of delivery must be modified in real time according to current patient prognoses.   
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